HilleVax, Inc. (HLVX)
NASDAQ$1.765+0.03 (1.73%)
Market Cap
$86.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
270 of 924
Rank in Industry
155 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
HLVX Insider Trading Activity
HLVX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $149,550 | 2 | 12 |
Sells | $901,735 | 15 | 88 |
Related Transactions
| Frazier Life Sciences X, L.P. | 10 percent owner | 1 | $128,325 | 0 | $0 | $128,325 |
| McLoughlin Sean | Chief Operating Officer | 1 | $21,225 | 0 | $0 | $21,225 |
| Maltbie Shane | Chief Financial Officer | 0 | $0 | 2 | $15,117 | $-15,117 |
| HERSHBERG ROBERT | See Remarks | 0 | $0 | 2 | $48,661 | $-48,661 |
| Kohli Aditya | director | 0 | $0 | 11 | $837,957 | $-837,957 |
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Insider Activity of HilleVax, Inc.
Over the last 12 months, insiders at HilleVax, Inc. have bought $149,550 and sold $901,735 worth of HilleVax, Inc. stock.
On average, over the past 5 years, insiders at HilleVax, Inc. have bought $15.07M and sold $493.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Frazier Life Sciences X, L.P. (10 percent owner) — $128,325. McLoughlin Sean (Chief Operating Officer) — $21,225.
The last purchase of 8,850 shares for transaction amount of $128,325 was made by Frazier Life Sciences X, L.P. (10 percent owner) on 2024‑04‑04.
List of Insider Buy and Sell Transactions, HilleVax, Inc.
| 2025-02-11 | Sale | HERSHBERG ROBERT | See Remarks | 11,901 0.0232% | $1.76 | $21,003 | +1.68% | |
| 2025-02-11 | Sale | Maltbie Shane | Chief Financial Officer | 4,345 0.0084% | $1.76 | $7,659 | +1.68% | |
| 2025-02-04 | Sale | HERSHBERG ROBERT | See Remarks | 14,634 0.0291% | $1.89 | $27,658 | -4.45% | |
| 2025-02-04 | Sale | Maltbie Shane | Chief Financial Officer | 3,946 0.0078% | $1.89 | $7,458 | -4.45% | |
| 2024-05-22 | Sale | Kohli Aditya | director | 6,000 0.0126% | $14.73 | $88,372 | -86.78% | |
| 2024-05-21 | Sale | Kohli Aditya | director | 6,000 0.0118% | $14.21 | $85,230 | -87.13% | |
| 2024-05-20 | Sale | Kohli Aditya | director | 6,000 0.0129% | $15.45 | $92,689 | -87.09% | |
| 2024-05-03 | Sale | Kohli Aditya | director | 723 0.0015% | $14.15 | $10,233 | -86.19% | |
| 2024-05-02 | Sale | Kohli Aditya | director | 6,000 0.0121% | $14.01 | $84,081 | -86.59% | |
| 2024-05-01 | Sale | Kohli Aditya | director | 175 0.0004% | $14.03 | $2,456 | -86.10% | |
| 2024-04-05 | Sale | Kohli Aditya | director | 6,000 0.012% | $14.44 | $86,640 | -86.91% | |
| 2024-04-04 | Sale | Kohli Aditya | director | 6,000 0.0122% | $14.71 | $88,245 | -86.90% | |
| 2024-04-04 | Frazier Life Sciences X, L.P. | 10 percent owner | 8,850 0.0178% | $14.50 | $128,325 | -86.90% | ||
| 2024-04-03 | Sale | Kohli Aditya | director | 6,000 0.0122% | $14.93 | $89,582 | -87.18% | |
| 2024-03-28 | McLoughlin Sean | Chief Operating Officer | 1,250 0.0026% | $16.98 | $21,225 | -88.57% | ||
| 2024-03-20 | Sale | Kohli Aditya | director | 6,000 – | $164,221.00 | $985.33M | -88.14% | |
| 2024-03-19 | Sale | Kohli Aditya | director | 6,000 0.0126% | $17.42 | $104,492 | -89.04% | |
| 2024-03-18 | Sale | Kohli Aditya | director | 6,000 0.0129% | $17.66 | $105,937 | -88.99% | |
| 2024-03-08 | Sale | Kohli Aditya | director | 6,000 0.0128% | $18.66 | $111,959 | -89.63% | |
| 2024-03-07 | Sale | Kohli Aditya | director | 6,000 0.0124% | $18.37 | $110,213 | -89.73% |
Total: 35
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Frazier Life Sciences X, L.P. | 10 percent owner | 8544187 17.1549% | $14.78M | 1 | 0 | |
| McLoughlin Sean | Chief Operating Officer | 1250 0.0025% | $2,162.50 | 1 | 0 | |
| Heron Patrick J | 8535337 17.1371% | $14.77M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$4,786,289 | 136 | 5.55% | $90.47M | |
$49,091,668 | 110 | 13.11% | $78.19M | |
$155,580,641 | 77 | -24.21% | $83.64M | |
$47,282,828 | 47 | -17.38% | $90.39M | |
$329,102,560 | 42 | 30.96% | $77.11M |
HLVX Institutional Investors: Active Positions
| Increased Positions | 43 | +58.11% | 4M | +12.18% |
| Decreased Positions | 28 | -37.84% | 3M | -9.09% |
| New Positions | 10 | New | 3M | New |
| Sold Out Positions | 14 | Sold Out | 2M | Sold Out |
| Total Postitions | 89 | +20.27% | 36M | +3.09% |
HLVX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Frazier Life Sciences Management, L.P. | $19,005.00 | 21.23% | 10.62M | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $8,807.00 | 9.84% | 4.92M | 0 | 0% | 2024-12-31 |
| Lightspeed Management Company, L.L.C. | $4,191.00 | 4.68% | 2.34M | +2M | New | 2024-12-31 |
| Blackrock, Inc. | $3,872.00 | 4.33% | 2.16M | +29,234 | +1.37% | 2024-12-31 |
| Franklin Resources Inc | $3,504.00 | 3.92% | 1.96M | 0 | 0% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $3,370.00 | 3.77% | 1.88M | 0 | 0% | 2024-12-31 |
| Carlyle Group Inc. | $3,291.00 | 3.68% | 1.84M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $2,875.00 | 3.21% | 1.61M | +32,789 | +2.08% | 2024-12-31 |
| Balyasny Asset Management L.P. | $1,795.00 | 2.01% | 1M | -12,057 | -1.19% | 2024-12-31 |
| Stepstone Group Lp | $1,480.00 | 1.65% | 826,569 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.